Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-7058 + SHR-9839 + SHR-1316
- Development stage
- Unknown
- Lead developer
- Shandong Suncadia Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
HRS-7058 + SHR-9839 + SHR-1316 is a combination therapy being developed by Shandong Suncadia Medicine, a subsidiary of Jiangsu Hengrui Pharmaceuticals, for the treatment of advanced malignant solid tumors. This triplet regimen consists of **HRS-7058**, a small molecule inhibitor of extracellular signal-regulated kinase 1 and 2 (ERK1/2); **SHR-9839**, a monoclonal antibody targeting the immune checkpoint T-cell immunoreceptor with Ig and ITIM domains (TIGIT); and **SHR-1316** (adebrelimab), a humanized monoclonal antibody targeting programmed cell death 1 ligand 1 (PD-L1). The combination is designed to simultaneously inhibit the MAPK/ERK signaling pathway, which is frequently dysregulated in cancer to drive proliferation, and block two distinct immunosuppressive pathways (PD-L1 and TIGIT) to restore and enhance the anti-tumor activity of T cells. It is currently being evaluated in Phase II clinical trials.
- Other names
- HRS-7058 + SHR-9839 + adebrelimab
02
Targets
MAPK3 (Mitogen-activated protein kinase 1)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on HRS-7058 + SHR-9839 + SHR-1316.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-7058 + SHR-9839 + SHR-1316.